Chemical Compound Review:
Vamidex (2S)-2-[[4-[(2,7-dimethyl-4- oxo-1H...
Synonyms:
Plevitrexed, CHEMBL126648, AG-K-40617, BGC9331, ZD-9331, ...
Rader,
Clarke-Pearson,
Moore,
Carson,
Holloway,
Kao,
Wiznitzer,
Douglass,
de Jonge,
Punt,
Sparreboom,
Planting,
Peters,
van De Schraaf,
Jackman,
Smith,
de Mulder,
Verweij,
Aherne,
Hardcastle,
Ward,
Dobinson,
Crompton,
Valenti,
Brunton,
Jackman,
Jackman,
Kimbell,
Aherne,
Brunton,
Jansen,
Stephens,
Smith,
Wardleworth,
Boyle,
Petruzelka,
Jackman,
Melin,
Kimbell,
Brunton,
Aherne,
Theti,
Walton,
Rots,
Pieters,
Peters,
van Zantwijk,
Mauritz,
Noordhuis,
Willey,
Hählen,
Creutzig,
Janka-Schaub,
Kaspers,
Veerman,
Jansen,
- Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. de Jonge, M.J., Punt, C.J., Sparreboom, A., Planting, A.S., Peters, M.E., van De Schraaf, J., Jackman, A., Smith, R., de Mulder, P.H., Verweij, J. J. Clin. Oncol. (2002)
- Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. Goh, B.C., Ratain, M.J., Bertucci, D., Smith, R., Mani, S., Vogelzang, N.J., Schilsky, R.L., Hutchison, M., Smith, M., Averbuch, S., Douglass, E. J. Clin. Oncol. (2001)
- Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Geller, J., Petak, I., Szucs, K.S., Nagy, K., Tillman, D.M., Houghton, J.A. Clin. Cancer Res. (2003)
- A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Schwartz, G.H., Jones, C.B., Garrison, M., Patnaik, A., Takimoto, C., McCreery, H., Skinner, M., Tolcher, A.W., Rowinsky, E.K. Investigational new drugs. (2004)
- A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Smith, D., Gallagher, N. Eur. J. Cancer (2003)
- Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Rots, M.G., Pieters, R., Peters, G.J., van Zantwijk, C.H., Mauritz, R., Noordhuis, P., Willey, J.C., Hählen, K., Creutzig, U., Janka-Schaub, G., Kaspers, G.J., Veerman, A.J., Jansen, G. Blood (1999)
- BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Gibbs, D.D., Theti, D.S., Wood, N., Green, M., Raynaud, F., Valenti, M., Forster, M.D., Mitchell, F., Bavetsias, V., Henderson, E., Jackman, A.L. Cancer Res. (2005)
- P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Geller, J.I., Szekely-Szucs, K., Petak, I., Doyle, B., Houghton, J.A. Cancer Res. (2004)
- Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Bilenker, J.H., Stevenson, J.P., Flaherty, K.T., Algazy, K., McLaughlin, K., Haller, D.G., Giantonio, B.J., Koehler, M., Garcia-Vargas, J.E., O'Dwyer, P.J. Cancer Chemother. Pharmacol. (2004)
- Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Aherne, G.W., Hardcastle, A., Ward, E., Dobinson, D., Crompton, T., Valenti, M., Brunton, L., Jackman, A.L. Clin. Cancer Res. (2001)
- Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Jackman, A.L., Kimbell, R., Aherne, G.W., Brunton, L., Jansen, G., Stephens, T.C., Smith, M.N., Wardleworth, J.M., Boyle, F.T. Clin. Cancer Res. (1997)
- Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Welsh, S.J., Titley, J., Brunton, L., Valenti, M., Monaghan, P., Jackman, A.L., Aherne, G.W. Clin. Cancer Res. (2000)
- The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Theti, D.S., Jackman, A.L. Clin. Cancer Res. (2004)
- The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Webley, S.D., Welsh, S.J., Jackman, A.L., Aherne, G.W. Br. J. Cancer (2001)
- Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Rees, C., Beale, P., Trigo, J.M., Mitchell, F., Jackman, A., Smith, R., Douglass, E., Judson, I. Clin. Cancer Res. (2003)
- Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Van Triest, B., Pinedo, H.M., Giaccone, G., Peters, G.J. Ann. Oncol. (2000)
- Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz, R., Peters, G.J., Priest, D.G., Assaraf, Y.G., Drori, S., Kathmann, I., Noordhuis, P., Bunni, M.A., Rosowsky, A., Schornagel, J.H., Pinedo, H.M., Jansen, G. Biochem. Pharmacol. (2002)
- Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor. Kobayashi, H., Takemura, Y., Miyachi, H. Cancer Chemother. Pharmacol. (1998)
- A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Jackman, A.L., Melin, C.J., Kimbell, R., Brunton, L., Aherne, G.W., Theti, D.S., Walton, M. Biochim. Biophys. Acta (2002)
- A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Rader, J.S., Clarke-Pearson, D., Moore, M., Carson, L., Holloway, R., Kao, M.S., Wiznitzer, I., Douglass, E.C. Gynecol. Oncol. (2003)
- Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Petruzelka, L. Anticancer Drugs (2003)